Estrella Immunopharma (ESLA) Enterprise Value (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Enterprise Value of -$1.9 million for Q1 2026, down 357.3% year-over-year from $749082.7 in Q1 2025, and down 39.23% quarter-over-quarter from -$1.4 million in Q4 2025.
Estrella Immunopharma (ESLA) Enterprise Value (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Enterprise Value for 6 consecutive years, with -$1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 357.3% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at -$1.9 million (down 357.3% YoY), while the FY2025 annual figure was -$1.4 million, down 50.97% from the prior year.
- Enterprise Value slipped to -$1.9 million in Q1 2026 per ESLA's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$29390.0 in Q1 2023 and bottomed at -$22.1 million in Q3 2023.
- Historically, Enterprise Value has averaged -$3.1 million across 5 years, with a median of -$1.4 million in 2025.
- Annual changes were most pronounced in 2023 — Enterprise Value tumbled 29916.81% — and 2024, when it surged 91.87%.
- Estrella Immunopharma's Enterprise Value stood at -$40802.0 in 2022, then sank by 22070.52% to -$9.0 million in 2023, then surged by 89.86% to -$916916.0 in 2024, then sank by 50.97% to -$1.4 million in 2025, then plunged by 39.23% to -$1.9 million in 2026.
- Business Quant data shows ESLA's Enterprise Value at -$1.9 million in Q1 2026, -$1.4 million in Q4 2025, and -$1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.87 Bn | 78.87 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.40 Bn | 60.22 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.36 Bn | 54.22 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.91 Bn | 28.60 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.17 Bn | 9.78 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 2.12 Bn |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | -146,670.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -146,670.00 |
| Mar 31, 2026 | -1.93 Mn |
| Dec 31, 2025 | -1.38 Mn |
| Sep 30, 2025 | -1.60 Mn |
| Jun 30, 2025 | -1.30 Mn |
| Mar 31, 2025 | -421,473.00 |
| Dec 31, 2024 | -916,916.00 |
| Sep 30, 2024 | -1.80 Mn |
| Jun 30, 2024 | -4.17 Mn |
| Mar 31, 2024 | -4.70 Mn |
| Dec 31, 2023 | -9.05 Mn |
| Sep 30, 2023 | -22.14 Mn |
| Jun 30, 2023 | -2.48 Mn |
| Mar 31, 2023 | -29,390.00 |
| Dec 31, 2022 | -40,802.00 |
| Sep 30, 2022 | -73,752.00 |
| Jun 30, 2022 | -88,281.00 |
| Mar 31, 2022 | -321,724.00 |
| Dec 31, 2021 | -478,868.00 |
| Sep 30, 2021 | -321,724.00 |